Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to investigate the effects of enzymatic treatment to reduce GOS (galactooligosaccharides) in legume-based crackers in IBS (irritable bowel syndrome) persons. The crackers are pea-based: the control crackers contain high amounts of GOS, while the enzymatically treated crackers contain a minimal amount of GOS. The participants will eat each type of cracker for three days (daily dose of 12 crackers) and report their gut symptoms (e.g. flatulence, stomach pain, bloating) by using a mobile app. There is a washout period of four days between the different crackers. In addition, the participants will keep food records on the cracker eating days as well as collect five fecal samples during the study. The participants will also report their physical activity and the number of defecations on each day. The study is carried out in a double-blinded crossover setting.


Clinical Trial Description

A human intervention study with volunteers suffering from either irritable bowel syndrome (IBS) or functional bloating (FB) will be carried out to investigate the effects of enzymatic treatment of pea-based product on gastrointestinal symptoms and gut microbiota composition as well as hydrogen production due to carbohydrate fermentation. Enzyme-treated product will be compared to a control product. The aim of the study is to investigate, whether enzyme-treated cracker, compared to a control product, will reduce gastrointestinaI symptoms, or have an impact on fecal microbiome or carbohydrate fermentation measured by breath hydrogen concentration. The effects of eating enzyme-treated crackers on food intake, exercise and stool frequency will also be investigated. The study is carried out in a randomized, double-blinded, placebo-controlled crossover design. The study includes two 1-week treatment periods with 1-week run-in period before the intervention. Participants (N=35 at the maximum) are adult males and females who meet Rome IV criteria for IBS or FB. Exclusion criteria will be as follows: - coeliac disease - inflammatory bowel disease - pregnancy or breastfeeding - antibiotics within the last 3 months - colonoscopy and preparations for it within 4 weeks During both treatment weeks each participant will receive three-day portion of either α-galactosidase-treated or control pea-based crackers. The participants will be advised to avoid foods that trigger their gastrointestinaI symptoms and otherwise follow their habitual diets for the whole 3-week study period. They will be asked to report severity of nine gastrointestinaI symptoms, keep food record, collect fecal samples, measure breath hydrogen and report their physical activity as well as stool frequency. The participants will report their gastrointestinal symptoms throughout the study weeks (twice a day on cracker eating days, once on washout days). Physical activity and stool frequency will also be reported daily. Fecal samples will be collected during the run-in period (at baseline) and on third and seventh day of each treatment week. Breath hydrogen will be measured on second day of both treatment weeks. Nutrient intake and food consumption will be analyzed from 3-day food records during the run-in week and each treatment week (total 9 days). Nutrient intake will be calculated using a new Finnish 'Aromi Diet' software. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05118243
Study type Interventional
Source University of Helsinki
Contact Anne-Maria Pajari
Phone +35829415820
Email [email protected]
Status Recruiting
Phase N/A
Start date September 6, 2021
Completion date June 2022

See also
  Status Clinical Trial Phase
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Active, not recruiting NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Not yet recruiting NCT05054309 - A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Enrolling by invitation NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A
Completed NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients N/A
Recruiting NCT04074421 - Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D Phase 4
Completed NCT04348760 - Study of Inflammatory Markers and Symptom Severity in Personalized Nutritional Intervention in IBS N/A
Recruiting NCT03555188 - TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial Phase 3
Completed NCT04543474 - Treatment Efficacy of Low FODMAP Versus Low Lactose Diet in IBS Patients N/A
Recruiting NCT04060121 - Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders
Recruiting NCT04129762 - Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With IBS and Dyspepsia N/A
Completed NCT04817683 - Study on the Relationship Between Mobile Phone Addiction and Functional Gastrointestinal Disorders
Completed NCT04256551 - Effects of a Novel Machine Learning Mobile App on Diet Adherence in Individuals Following the Low Fodmap Diet N/A
Not yet recruiting NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Not yet recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A